- Home
- BDRX vs CDT Comparison
BDRX vs CDT Comparison
Compare BDRX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | CDT |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BDRX | CDT |
|---|---|---|
| Price | $1.21 | $1.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 517.1K | ★ 1.2M |
| Earning Date | 09-12-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $0.91 |
| 52 Week High | $92.00 | $384.00 |
Technical Indicators
Market Signals| Indicator | BDRX | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 28.35 | 40.54 |
| Support Level | $1.22 | $0.91 |
| Resistance Level | $1.38 | $1.18 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 0.93 | 40.77 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.